BioNTech-JPM-2023.pdf

1、January 10,2023Ugur Sahin,M.D.CEO and Co-FounderThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,as amended,including,but not limited to,statements concerning:BioNTechs expectedrevenues and net profit related to sales of

2、 BioNTechs COVID-19 vaccine,referred to as COMIRNATYwhere approved for use under full or conditional marketing authorization,in territories controlled by BioNTechscollaboration partners,particularly for those figures that are derived from preliminary estimates provided by BioNTechs partners;BioNTech

3、s pricing and coverage negotiations with governmental authorities,privatehealth insurers and other third-party payors after BioNTechs initial sales to national governments;the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine;competition fromother COVID-19

4、vaccines or related to BioNTechs other product candidates,including those with different mechanisms of action and different manufacturing and distribution constraints,on the basis of,among otherthings,efficacy,cost,convenience of storage and distribution,breadth of approved use,side-effect profile a

5、nd durabilityof immune response;the rate and degree ofmarket acceptance of BioNTechs COVID-19 vaccineand,if approved,BioNTechs investigational medicines;the initiation,timing,progress,results,and cost of BioNTechs research and development programs,including those relating to additional formulations

6、ofBioNTechs COVID-19 vaccine,and BioNTechs current and future preclinical studies and clinical trials,including statements regarding the timing of initiation and completion of studies or trials and related preparatorywork,the period during which the results of the trials will become available and Bi